Compounds of formula I: ##STR1## [wherein: X represents --CH.dbd.CH--, --CH.dbd.CR--, --CR.dbd.CR--, --CO--, --O--, --NH--, --NR--, S--, --SO--, --SO.sub.2 --, --CH.dbd.N--, --CR.dbd.N--, --CH.dbd.N(O)--, --CR.dbd.N(O)-- or any other atom or group of atoms capable of forming a S-- or 6-membered heterocyclic ring; Y.sup.1, Y.sup.2 and Y.sup.3 independently represent hydrogen or halogen; R.sup.1, R.sup.2 and R.sup.3 are independently represent hydrogen, halogen, hydrocarbyl (--R), hydroxyl (--OH), hydrocarbyloxy (--O--R), mercapto (--SH), hydrocarbylthio (--S--R), hydrocarbylsulfinyl (--SO--R), hydrocarbylsulfonyl (--SO.sub.2 --R), nitro (--NO.sub.2), amino (--NH.sub.2), hydrocarbylamino (--NHR), bis(hydrocarbyl)amino (--NR.sub.2), hydrocarbylcarbonylamino (--NH--CO--R), cyano (--CN), carbamoyl (--CONH.sub.2), hydrocarbylcarbarnoyl (--CONHR), bis(hydrocarbyl)carbamoyl (--CONR.sub.2), carboxyl (--CO.sub.2 H), hydrocarbyloxycarbonyl (--CO.sub.2 R), formyl (--CHO), hydrocarbylcarbonyl (--COR), hydrocarbylcarbonyloxy (--OCOR), optionally substituted heteroaryl or optionally substituted heterocyclic; and the hydrocarbyl group R is a straight or branched chain hydrocarbyl group selected from alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl and aralkynyl, which may optionally be substituted by one or more substituents, selected from those defined above in relation to R1, R2 and R3]; are of use in the manufacture of a medicament for the treatment including prophylaxis of disease mediated by the activation of GSK-3.
The present invention provides novel compounds represented by formula I: ##STR1## or pharmaceutically acceptable salts thereof useful for treating flaviviridae viral infection.
Compounds represented by formula: ##STR00001## wherein X, Y and Z are as defined herein, pharmaceutically acceptable salts thereof, and related compounds, are suitable for use in treating or preventing a Flaviviridae viral infection in a host.
The (R) and (S) enantiomers of a compound of formula I ##STR00001## are novel antiproliferative therapeutic agents. These compounds have HDAC inhibitor activity and are useful in the treatment of cancer. Also disclosed are methods of making and using compounds of formula (I), as well as pharmaceutical compositions containing compounds of formula (I).
Compounds represented by formula I: ##STR00001## or pharmaceutically acceptable salts and solvates thereof, wherein R.sub.1, X, Y, Y.sub.1, and Z are as defined herein, are useful for treating flaviviridae viral infections.
